Safety of pulmonary vein isolation in atrial fibrillation patients treated with dabigatran when idarucizumab is available (RCDD code: VIII)

Edward Koźluk1, Dariusz Rodkiewicz1*, Agnieszka Piątkowska1,2, Paweł T. Matusik3,4, Grzegorz Opolski1

1 1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland; 2 Chair of Emergency Medicine, Wrocław Medical University, Wrocław, Poland; 3 Department of Electrocardiology, the John Paul II Hospital, Kraków, Poland; 4 Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland

Abstract

Patients with atrial fibrillation (AF) are at increased risk of stroke and systemic thromboembolism and prevention of such episodes is ensured by choosing appropriate anticoagulation. In paroxysmal drug-refractory AF, catheter ablation is the recommended choice of treatment. The decision on whether to stop administration of oral anticoagulant before catheter ablation procedures is often unclear. We present the case of a 67-year-old hypertensive woman with a 5-year history of symptomatic, drug-refractory paroxysmal AF, who was admitted for pulmonary vein isolation (PVI) and was anticoagulated with dabigatran. After successful transseptal puncture, an intravenous injection of 10 000 units of heparin was administered. Radiofrequency ablation was initiated at the left pulmonary trunk. After the second application of radiofrequency ablation, a drop in arterial blood pressure to 70/50 mmHg was observed. Urgent echocardiography revealed the presence of fluid within the epicardial surface of the left ventricular apex up to 19 mm, behind the right ventricle and right atrium up to 11 mm. Subsequently, all catheters were removed from the left atrium, and 50 mg of protamine sulfate, dopamine, and intravenous fluids were immediately administered. Idarucizumab was urgently delivered to the catheterisation laboratory and was available during patient hospitalisation in the intensive care unit. However, prior to patient discharge, echocardiography revealed only a trace amount of fluid in the pericardium and the use of idarucizumab was not indicated. Interruption of anticoagulation treatment with dabigatran before ablation is not required. Idarucizumab increases the safety of PVI in patients treated with dabigatran. JRCD 2018; 3 (8): 281–283

Key words: rare disease, atrial fibrillation, ablation, pulmonary vein isolation, anticoagulation, dabigatran

Background

Patients with atrial fibrillation (AF) who are at substantial risk of stroke and systemic thromboembolism require appropriate anticoagulation [1]. The CHA2DS2-VASc score and biomarker-based approaches were developed to aid in the assessment of stroke risk in patients with AF [2]. According to current European Society of Cardiology guidelines and international expert consensus, patients with paroxysmal AF and failure of pharmacologic therapy to improve symptoms in class IA are recommended to undergo catheter ablation [3, 4]. It was previously shown that cryoballoon ablation was noninferior to radiofrequency ablation with regard to efficacy and overall safety in this clinical indication [5].

Case presentation

A 67-year-old hypertensive woman with a 5-year history of symptomatic (European Heart Rhythm Association [EHRA] symptom scale of III), drug-refractory paroxysmal AF, was admitted for pulmonary vein isolation (PVI). She had a CHA2DS2-VASc score of 2 and was anticoagulated with dabigatran 150 mg twice daily. The patient received her last dose of dabigatran the evening before
the procedure. On admission, her international normalised ratio (INR) was 1.36 (normal range 0.9–1.3), activated partial thromboplastin time (APTT) 66.3 seconds (normal range 25–37 seconds), and prothrombin time (PT) 15.5 seconds (normal range 13–17 seconds). The electrocardiogram (ECG) showed AF with fast ventricular rate in the range of 130–180 per minute. Prior to ablation, thrombi in the left atrium were excluded via transoesophageal echocardiography. Using a transfemoral approach under Ensite navigation (St. Jude Medical, St. Paul, Minnesota, USA), diagnostic catheters (Hagmed, Rawa Mazowiecka, Poland) were placed in the apex of the right ventricle and coronary sinus. Subsequently, successful transseptal puncture using fluoroscopy and invasive blood pressure monitoring was performed, followed by an intravenous injection of 10 000 units of heparin. With the use of the Ensite system and pulmonary vein ablation catheter (PVAC) (Medtronic, Minneapolis, Minnesota, USA), electroanatomical mapping of the left atrium was performed (Figure Panel A) and radiofrequency ablation was initiated at the left pulmonary trunk. After the second application of radiofrequency ablation, a drop in arterial blood pressure to 70/50 mmHg was observed. Urgent echocardiography revealed presence of fluid with-in the epicardial surface of the left ventricular apex up to 19 mm (Figure Panel B) and behind the right ventricle and right atrium up to 11 mm (Figure Panel C), indicating moderate pericardial ef-fusion. The patient reported weakness and dyspnoea. Subsequently, all catheters were removed from the left atrium, and 50 mg of protamine sulfate, dopamine, and intravenous fluids were im-mediately administered. Idarucizumab was urgently delivered to the catheterisation laboratory and was accessible during patient hospitalisation in the intensive care unit. The overall procedure time was 100 minutes; total fluoroscopy exposure was 3 minutes and 45 seconds (335.9 cGy cm²). Prior to discharge, echocardiogra-phy revealed only a trace amount of fluid in the pericardium (Figure Panel D). Because of this, there was no indication for the use of idarucizumab.

**Discussion and review of literature**

Consideration of indications and contraindications for anticoagulation is crucial in patients with AF, and non-vitamin K antagonist oral anticoagulants play an increasing role in the treatment of patients with AF (Table) [3, 6, 7]. The decision on whether to interrupt oral anticoagulant treatment before cardiovascular implantable electronic device implantation and catheter ablation procedures is often unclear. These are generally considered as interventions with low bleeding risk, unless a complex anatomical setting is present or complex procedures are performed, respectively. However, complex left-sided ablations, including PVI, are regarded as interventions with a high bleeding and increased thromboembolic risk [7]. The current EHRA Practical Guide on the use of non-vitamin K antagonist oral anticoagulants (NOAC) recommends catheter ablation in patients who have been therapeutically anticoagulated with NOAC, generally without interruption or with a short cessation period of such treatment, depending on several factors, including CHA2DS2-VASc score, creatinine clearance, operator experience, and routine use of heparin before the first transseptal puncture [7]. Performance of catheter ablation during the use of dabigatran was tested in the Randomized Evaluation of Dabigatran Etxelate Compared to Warfarin in Pulmonary Vein Ablation: Assessment of an Uninterrupted Periprocedural Anticoagulation Strategy (RE‑CIRCUIT) trial [8]. In this trial, patients received dabigatran at the usual time in the morning on the day of ablation and was associated with fewer bleeding complications than uninterrupted
Koźluk, et al.

warfarin [8]. On the other hand, in cases of bleeding, measurement of the anticoagulant effect of the oral direct inhibitor of thrombin, may be required [9]. However, measurement of dabigatran plasma concentration is not widely available in all hospitals. Therefore, APTT may be useful in the assessment of the relative degree of anticoagulation with dabigatran. In patients receiving 150mg of dabigatran twice daily the median trough APTT is ~1.5 times higher than the level observed in controls, while a ratio of >2.5 may indicate supratherapeutic levels [9].

Moreover, a reversal agent for dabigatran (idarucizumab) is currently available, while a reversal agent for factor Xa inhibitors will likely be available in daily clinical practice in the near future [10, 11]. Idarucizumab was successfully tested in patients with serious bleeding and in those who require urgent procedures [10]. In the Reversal Effects of Idarucizumab on Active Dabigatran (RE-VERSE AD) study, idarucizumab was given in two separate bolus infusions, no more than 15 minutes apart (total of 5 g of idarucizumab), to patients in whom the median time since last intake of dabigatran was 15.4 hours (in 36% of patients, the last intake was <12 hours, while in 6% of patients this time was ≥48 hours) [10].

There are published reports which show the importance of idarucizumab in specific urgent medical situations [12–14]. However, this case report and review of the literature highlight the potential clinical utility of idarucizumab in cardiology during catheter ablation. Pericardial effusion during pulmonary vein isolation occurs in < 1% of cases, however, if present, could lead to cardiac tamponade and death [15]. Therefore, the choice of an optimal anticoagulant agent is crucial.

**Conclusion**

There is no necessity to interrupt anticoagulation treatment with dabigatran before AF ablation if idarucizumab is available. Idarucizumab increases the safety of PVI in patients treated with dabigatran.